These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22581823)

  • 1. Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry.
    Sweeney J; Brightling CE; Menzies-Gow A; Niven R; Patterson CC; Heaney LG;
    Thorax; 2012 Aug; 67(8):754-6. PubMed ID: 22581823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry.
    Heaney LG; Brightling CE; Menzies-Gow A; Stevenson M; Niven RM;
    Thorax; 2010 Sep; 65(9):787-94. PubMed ID: 20805172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma.
    Murphy AC; Proeschal A; Brightling CE; Wardlaw AJ; Pavord I; Bradding P; Green RH
    Thorax; 2012 Aug; 67(8):751-3. PubMed ID: 22436168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry.
    O'Neill S; Sweeney J; Patterson CC; Menzies-Gow A; Niven R; Mansur AH; Bucknall C; Chaudhuri R; Thomson NC; Brightling CE; O'Neill C; Heaney LG;
    Thorax; 2015 Apr; 70(4):376-8. PubMed ID: 24917087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of budesonide or nedocromil in children with asthma.
    ; Szefler S; Weiss S; Tonascia J; Adkinson NF; Bender B; Cherniack R; Donithan M; Kelly HW; Reisman J; Shapiro GG; Sternberg AL; Strunk R; Taggart V; Van Natta M; Wise R; Wu M; Zeiger R
    N Engl J Med; 2000 Oct; 343(15):1054-63. PubMed ID: 11027739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.
    Brodlie M; McKean MC; Moss S; Spencer DA
    Arch Dis Child; 2012 Jul; 97(7):604-9. PubMed ID: 22685051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up after two years of asthma treatment guided by airway responsiveness in children.
    Nuijsink M; Vaessen-Verberne AA; Hop WC; Sterk PJ; Duiverman EJ; de Jongste JC;
    Respir Med; 2013 Jul; 107(7):981-6. PubMed ID: 23672993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
    Massanari M; Milgrom H; Pollard S; Maykut RJ; Kianifard F; Fowler-Taylor A; Geba GP; Zeldin RK
    Clin Pediatr (Phila); 2009 Oct; 48(8):859-65. PubMed ID: 19564449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry.
    Sweeney J; Patterson CC; Menzies-Gow A; Niven RM; Mansur AH; Bucknall C; Chaudhuri R; Price D; Brightling CE; Heaney LG;
    Thorax; 2016 Apr; 71(4):339-46. PubMed ID: 26819354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial.
    Ramsay CF; Pearson D; Mildenhall S; Wilson AM
    Thorax; 2011 Jan; 66(1):7-11. PubMed ID: 20956393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid response in refractory asthmatics.
    Jang AS
    Korean J Intern Med; 2012 Jun; 27(2):143-8. PubMed ID: 22707883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
    Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
    J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin.
    Spahn JD; Leung DY; Chan MT; Szefler SJ; Gelfand EW
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):421-6. PubMed ID: 10069875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
    Chen HC; Huang CD; Chang E; Kuo HP
    BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.